Literature DB >> 15539050

Late relapse/sustained abstinence among former smokers: a longitudinal study.

David W Wetter1, Ludmila Cofta-Gunn, Rachel T Fouladi, Paul M Cinciripini, Dawen Sui, Ellen R Gritz.   

Abstract

BACKGROUND: Relapse remains the most refractory aspect of nicotine dependence, but little is known about relapse that occurs after a period of prolonged abstinence (i.e., "late relapse").
METHOD: The current study examined the prevalence and predictors of late relapse/sustained abstinence in a community-based, longitudinal cohort of former smokers surveyed at baseline and again 4 years later (n = 1143).
RESULTS: Late relapse rates declined precipitously and sustained abstinence increased as the duration of abstinence at baseline increased. Although the risk for late relapse appeared to be small when using a point prevalence definition of smoking, that risk increased substantially if fluctuations in smoking behavior over time were considered (i.e., many former smokers relapsed and then regained abstinence during the 4-year study period). Although there were a number of significant prospective predictors of late relapse/sustained abstinence, they did not retain their predictive ability after controlling for baseline duration of abstinence.
CONCLUSION: Although late relapse rates in the general population of former smokers appear low, and particularly so for individuals who have been abstinent for long periods of time, fluctuations between abstinence and smoking over time are not uncommon. How these fluctuations influence health or sustained abstinence over time is unclear. Because late relapse rates are generally low, interventions are likely to require careful targeting of at-risk individuals if they are to be efficacious and cost-effective.

Entities:  

Mesh:

Year:  2004        PMID: 15539050     DOI: 10.1016/j.ypmed.2004.04.028

Source DB:  PubMed          Journal:  Prev Med        ISSN: 0091-7435            Impact factor:   4.018


  40 in total

1.  Indicators of cigarette smoking dependence and relapse in former smokers who vape compared with those who do not: findings from the 2016 International Tobacco Control Four Country Smoking and Vaping Survey.

Authors:  Ann McNeill; Pete Driezen; Sara C Hitchman; K Michael Cummings; Geoffrey T Fong; Ron Borland
Journal:  Addiction       Date:  2019-08-15       Impact factor: 6.526

Review 2.  Economic evaluation of smoking-cessation therapies: a critical and systematic review of simulation models.

Authors:  Kristian Bolin
Journal:  Pharmacoeconomics       Date:  2012-07-01       Impact factor: 4.981

3.  The day-to-day process of stopping or reducing smoking: a prospective study of self-changers.

Authors:  Erica N Peters; John R Hughes
Journal:  Nicotine Tob Res       Date:  2009-06-26       Impact factor: 4.244

4.  The Relations Between False Positive and Negative Screens and Smoking Cessation and Relapse in the National Lung Screening Trial: Implications for Public Health.

Authors:  Melissa A Clark; Jeremy J Gorelick; JoRean D Sicks; Elyse R Park; Amanda L Graham; David B Abrams; Ilana F Gareen
Journal:  Nicotine Tob Res       Date:  2015-03-06       Impact factor: 4.244

5.  A qualitative study of smokers' responses to messages discouraging dual tobacco product use.

Authors:  Lucy Popova; Ganna Kostygina; Nicolas M Sheon; Pamela M Ling
Journal:  Health Educ Res       Date:  2014-01-17

6.  Cost-effectiveness of extended cessation treatment for older smokers.

Authors:  Paul G Barnett; Wynnie Wong; Abra Jeffers; Ricardo Munoz; Gary Humfleet; Sharon Hall
Journal:  Addiction       Date:  2013-12-13       Impact factor: 6.526

7.  Intranasal oxytocin dampens cue-elicited cigarette craving in daily smokers: a pilot study.

Authors:  Melissa A Miller; Anya Bershad; Andrea C King; Royce Lee; Harriet de Wit
Journal:  Behav Pharmacol       Date:  2016-12       Impact factor: 2.293

8.  Alternative tobacco product use and smoking cessation: a national study.

Authors:  Lucy Popova; Pamela M Ling
Journal:  Am J Public Health       Date:  2013-03-14       Impact factor: 9.308

9.  Cost-utility analysis of varenicline, an oral smoking-cessation drug, in Japan.

Authors:  Ataru Igarashi; Hiroki Takuma; Takashi Fukuda; Kiichiro Tsutani
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

10.  Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis.

Authors:  Lieven Annemans; Kristiaan Nackaerts; Pierre Bartsch; Jacques Prignot; Sophie Marbaix
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.